BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company developing novel antibacterial products for serious infections caused by multidrug-resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York City.
Chief Financial Officer Hernan Levett will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Lotte New York Palace (Kennedy II, 4th Floor). Additionally, CEO Dr. Marc Gitzinger will provide an on-demand presentation, available starting September 11, 2026, at 7:00 AM ET, with replays accessible for 90 days via the H.C. Wainwright platform or the BioVersys website.
The company's participation underscores its commitment to tackling the global threat of antimicrobial resistance (AMR), a public health crisis that the World Health Organization has identified as one of the top ten global health threats. BioVersys is advancing a multi-asset pipeline derived from its proprietary TRIC and Ansamycin Chemistry platforms, designed to overcome resistance mechanisms and block virulence production. Its lead programs target nosocomial infections caused by Acinetobacter baumannii (BV100, currently in Phase 3) and tuberculosis (alpibectir, in Phase 2, developed in collaboration with GlaxoSmithKline and a consortium led by the University of Lille).
The presentations at this prominent investment conference provide a platform for BioVersys to highlight recent milestones and future development plans to institutional investors and industry analysts. This exposure is critical as the company seeks to secure funding and partnerships to advance its late-stage clinical trials. The need for new antibiotics is urgent, as MDR bacteria cause an estimated 1.27 million deaths annually, according to a study published in The Lancet. BioVersys’ focus on novel mechanisms offers hope for patients with limited therapeutic options.
BioVersys' CEO and CFO will be available for one-on-one meetings during the conference, allowing for in-depth discussions with registered attendees. The company's presence at the conference reflects its strategic efforts to engage with the investment community and communicate the potential of its innovative approach to address unmet medical needs in infectious diseases.
For more information about the conference and BioVersys’ presentations, interested parties can visit the H.C. Wainwright platform or the BioVersys website. The company’s participation highlights the growing recognition of the importance of investing in antimicrobial research and development. As drug-resistant infections continue to rise, BioVersys aims to deliver new treatment options that can save lives and reduce the burden on healthcare systems worldwide.
